Pre-IPO Qyuns Therapeutics - Conservative About the Outlook
Qyuns’s pipeline lacks competitiveness, facing fierce competition.Together with bleak internationalization outlook, peak sales have obvious...
379 Views
China Healthcare Weekly (Sep.29) - Be Rational About Biotech Investment, R&D Team Layoffs, Huadong
It’s advised to establish rational expectation for Biotech's investment return. R&D team will be cut eventually during M&A/IPO. Huadong's valuation...
603 Views
United Laboratories International Holdings Placement (3933.HK) - Valuation Pullback Seems Inevitable
United Lab is facing a performance decline when the dividend period of the pandemic has subsided. Weight management/veterinary drug businesses have...
540 Views
Anti-Corruption in China Healthcare – the Impact and the Outlook
The share prices of China healthcare are now plummeting due to anti-corruption campaign, which will reach a climax in 23H2 (We'll post updates in...
784 Views
Lu DaoPei Medical Group Pre-IPO - Ramp up in Progress but Looks Promising
Lu Daopei Medical Group (1816743D CH) is looking to raise around US$400m in its upcoming Hong Kong IPO. LDPM has supported its growth through its...
404 Views